SAGE250117C27500
- 0.01
- 0.000.00%
Sage Therapeutics Newsroom
Stifel Maintains Hold on Sage Therapeutics, Lowers Price Target to $6
Sage Therapeutics Analyst Ratings
Stifel Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Cuts Target Price to $6
Mizuho Securities Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Announces Target Price $10
Mizuho Securities Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Agenus (AGEN) and SAGE Therapeutics (SAGE)
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $8 to $14
TD Cowen Maintains Hold on Sage Therapeutics, Lowers Price Target to $9
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $4 to $14
Truist Financial Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
Sage Therapeutics Price Target Maintained With a $4.00/Share by RBC Capital
SAGE Therapeutics: Hold Rating Amid Clinical Setbacks and Strategic Shifts
Wedbush Cuts Price Target on SAGE Therapeutics to $4 From $7, Maintains Neutral Rating
Sage Therapeutics Analyst Ratings
CCORF Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $9
Morgan Stanley Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $9
Morgan Stanley Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Cuts Target Price to $9
SAGE Therapeutics: Balancing Promising Sales Growth With Strategic Uncertainties – A Hold Rating
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $10 to $26
Sage Therapeutics Is Maintained at Perform by Oppenheimer